Literature DB >> 20523994

Endovenous ablation for the treatment of chronic venous insufficiency and venous ulcerations.

Christopher J Marrocco1, Marvin D Atkins, W Todd Bohannon, Thomas R Warren, Clifford J Buckley, Ruth L Bush.   

Abstract

OBJECTIVE: Conventional treatment of chronic venous disease with ulceration is layered compression dressings. Saphenous vein stripping is reserved for recurrent or nonhealing ulcers. This study examines outcomes of aggressive endovenous therapy in promoting ulcer healing and/or preventing ulcer recurrence. The role of additional perforator vein ablation also is analyzed.
METHODS: This retrospective chart review occurred during a 2.5-year time frame during which 356 patients with venous insufficiency were seen in our vein center and underwent 412 venous operations (56 with bilateral disease treated on separate dates). A cohort of 75 (21.1%) patients with severe chronic venous disease underwent 83 (20.1%) procedures (C5: n = 52, 63%; C6: n = 31, 37%); 8 patients had bilateral procedures. Data analysis included body-mass index (BMI), history of deep vein thrombosis (DVT) or previous vein surgery, and type of procedure (radiofrequency ablation (RFA) of greater saphenous vein (GSV) alone or GSV and perforator ablation (GSVP)). Complications, ulcer healing rates, and recurrent ulcerations were examined. Descriptive statistics are reported and contingency tables used when appropriate.
RESULTS: Overall, the patients were 63.5 +/- 13.4 years of age (men: n = 36, women: n = 39) with a BMI of 32.4 (range, 20.8-53.4). All of the patients had GSV insufficiency and 30 (44%) patients had deep vein incompetence. Only 19 (28%) patients had a history of a DVT and 13 (19%) had previous vein procedures. The 31 extremities with C6 disease had been treated conservatively with compression for an average of 7.6 +/- 4.2 (range, 1-156) months before undergoing ablation. Ablation site was GSV in 49 (72%) and GSVP in 19 (28%). Only two (2.9%) complications occurred: excessive hemosiderin staining and paresthesias each occurred in one patient. Of the C5 patients treated, two (4.7%) developed recurrent ulcerations and five (20%) C6 patients did not heal completely or developed a recurrent ulcer. There was no statistically significant difference in ulcer healing or recurrence rates between C5 and C6 patients treated with and without the addition of perforator interruption.
CONCLUSIONS: Chronic venous insufficiency with active or healed ulceration is commonly seen in our academic vein center. In this series, endovenous ablation allowed for excellent healing rates and acceptable recurrent ulcer rates. It is unclear from this small cohort whether the addition of perforator ablation was of benefit in improving venous hemodynamics.

Entities:  

Mesh:

Year:  2010        PMID: 20523994     DOI: 10.1007/s00268-010-0659-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

Review 1.  Impact of the calf perforators on the venous hemodynamics in primary varicose veins.

Authors:  C Recek
Journal:  J Cardiovasc Surg (Torino)       Date:  2006-12       Impact factor: 1.888

2.  Patterns of venous reflux in limbs with skin changes associated with chronic venous insufficiency.

Authors:  T A Lees; D Lambert
Journal:  Br J Surg       Date:  1993-06       Impact factor: 6.939

3.  Radiofrequency ablation of incompetent perforator veins.

Authors:  Eric Peden; Alan Lumsden
Journal:  Perspect Vasc Surg Endovasc Ther       Date:  2007-03

4.  Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease.

Authors:  J M Porter; G L Moneta
Journal:  J Vasc Surg       Date:  1995-04       Impact factor: 4.268

Review 5.  The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption.

Authors:  Thomas F O'Donnell
Journal:  J Vasc Surg       Date:  2008-10       Impact factor: 4.268

6.  Diagnosis and management of venous ulcers.

Authors:  Sandra C Carr
Journal:  Perspect Vasc Surg Endovasc Ther       Date:  2008-04-02

7.  Distribution and prevalence of reflux in the superficial and deep venous system in the general population--results from the Bonn Vein Study, Germany.

Authors:  Uldis Maurins; Barbara H Hoffmann; Christian Lösch; Karl-Heinz Jöckel; Eberhard Rabe; Felicitas Pannier
Journal:  J Vasc Surg       Date:  2008-06-30       Impact factor: 4.268

8.  Treatment of incompetent perforating veins using the radiofrequency ablation stylet: a pilot study.

Authors:  R R van den Bos; T Wentel; M H A Neumann; T Nijsten
Journal:  Phlebology       Date:  2009-10       Impact factor: 1.740

9.  Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial.

Authors:  Jamie R Barwell; Colin E Davies; Jane Deacon; Kate Harvey; Julia Minor; Antonio Sassano; Maxine Taylor; Jenny Usher; Clare Wakely; Jonathan J Earnshaw; Brian P Heather; David C Mitchell; Mark R Whyman; Keith R Poskitt
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

Review 10.  [Endovenous laser therapy: a new treatment for varicose veins].

Authors:  J van den Bremer; P P A Hedeman Joosten; F L Moll
Journal:  Ned Tijdschr Geneeskd       Date:  2007-04-28
View more
  3 in total

Review 1.  A review of the current management and treatment options for superficial venous insufficiency.

Authors:  Henry T Zhan; Ruth L Bush
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

2.  Prevention of venous leg ulcer recurrence.

Authors:  Manjunath M Shenoy
Journal:  Indian Dermatol Online J       Date:  2014-07

3.  Aspirin for Venous Ulcers: Randomised Trial (AVURT): study protocol for a randomised controlled trial.

Authors:  Helen Tilbrook; Rachael O Forsythe; Debbie Rolfe; Laura Clark; Martin Bland; Hannah Buckley; Ian Chetter; Liz Cook; Jo Dumville; Rhian Gabe; Keith Harding; Alison Layton; Ellie Lindsay; Catriona McDaid; Christine Moffatt; Ceri Phillips; Gerard Stansby; Peter Vowden; Laurie Williams; David Torgerson; Robert J Hinchliffe
Journal:  Trials       Date:  2015-11-10       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.